Are you working on data-sparse or novel targets? Join us June 11th to learn how Avammune progressed from early concepts to ...

Analysts and investors were unimpressed by Phase 2 data posted in the spring showing that an amylin analog developed by Roche ...

Pfizer showcased multiple late-breakers at the American Society of Clinical Oncology’s annual conference but its biggest data ...

In addition to a high rate of deaths, ADC Therapeutics’ Zynlonta plus rituximab showed no overall survival benefit in ...

When used alongside Merck’s Keytruda, Moderna’s personalized cancer vaccine halved the risk of death or disease recurrence in ...

The FDA must provide consistent and predictable regulatory frameworks if the U.S. is to maintain its leadership in gene ...

Drug production is expected to be one of the main drivers of employment growth in U.S. manufacturing through 2034, with the ...

Deal dynamics between Chinese biotechs and global pharma companies are changing fast, with the biotechs seeking higher ...

Massachusetts’ life sciences jobs declined 1% in 2025, according to a new MassBioEd report. However, the report is projecting ...

Celcuity’s gedatolisib doubled progression-free survival versus standard of care in certain patients with advanced breast ...

Government backing, deep scientific talent and a robust pharma heritage are helping France punch above its weight, but ...

Erik Paulsen is the chairman of the Institute for Gene Therapies and a former Member of Congress (MN-3), serving from 2009 to ...